Lymphoma: Role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging

Radiology

Volumn 203, Issue 3, 1997, Pages 795-800

  Moog, Florian ^a   Bangerter, Markus ^a   Diederichs, Christoph G ^a   Guhlmann, Albrecht ^a   Kotzerke, Jörg ^a   Merkle, Elmar ^a   Kolokythas, Orpheus ^a   Herrmann, Friedhelm ^a   Reske, Sven N ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Emission CT (ECT), comparative studies; Hodgkin disease, staging; Lymphoma, CT; Lymphoma, emission CT (ECT); Lymphoma, staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FUROSEMIDE; IOPAMIDOL; LYSINE DIATRIZOATE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; WHOLE BODY TOMOGRAPHY;

EID: 0030988191     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.203.3.9169707     Document Type: Article

References (60)

1. North LB, Wallace S, Lindell MM Jr, Jing BS, Fuller LM, Allen PK. Lymphography for staging of lymphomas: is it still a useful procedure? AJR 1993; 161:867-869.
2. Cassina P, Buchel H, Muller W, Martinoli S. How useful is mediastinoscopy today? Helv Chir Acta 1993; 59:861-865.
3. Castellino RA, Blank N, Hoppe RT, Cho C. Hodgkin's disease: contribution of chest CT in the initial staging evaluation. Radiology 1986; 160:603-605.
4. Neumann CH, Robert NJ, Canellos G, Rosenthal D. Computed tomography of the abdomen and pelvis in non-Hodgkin lymphoma. J Comput Assist Tomogr 1983; 7:846-850.
5. Tesoro-Tess JD, Balzarini L, Ceglia T, et al. Magnetic resonance imaging in the initial staging of Hodgkin's disease and non-Hodgkin lymphoma. Eur J Radiol 1991; 12:81-90.
6. Hamrick-Turner JE, Saif MF, Powers CI, Blumenthal BI, Royal SA, Iyer RV. Imaging of childhood non-Hodgkin lymphoma: assessment by histologic subtype. RadioGraphics 1994; 14:11-28.
7. Skillings JR, Bramwell V, Nicholson RL, Prato FS, Wells G. A prospective study of magnetic resonance imaging in lymphoma staging. Cancer 1991; 67:1838-1843.
8. Front D, Bar-Shalom R, Epelbaum R, et al. Early detection of lymphoma recurrence with gallium-67 scintigraphy. J Nucl Med 1993; 34:2101-2104.
9. Front D, Israel O, Epelbaum R, et al. Ga-67 SPECT before and after treatment of lymphoma. Radiology 1990; 175:515-519.
10. Anderson KC, Leonhard RCG, Canellos GP. High-dose gallium imaging in lymphoma. Am J Med 1983; 75:327-334.
11. Arita T, Kuramitsu T, Kawamura M, et al. Bronchogenic carcinoma: incidence of metastases to normal sized lymph nodes. Thorax 1995; 50:1267-1269.
12. Bailet JW, Abemayor E, Jabour BA, et al. Positron emission tomography: a new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy. Laryngoscope 1992; 102:281-288.
13. Stollfuss J, Glatting G, Friess H, Kocher F, Beger H, Reske SN. 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology 1995; 195:339-344.
14. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue FDG. Radiology 1991; 179:765-770.
15. Laubenbacher C, Saumweber D, Wagner-Manslau C, et al. Comparison of FDG-PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med 1995; 36:1747-1757.
16. Som P, Atkins HL, Bandophadhyah D. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18). J Nucl Med 1980; 21:670-675.
17. Warburg O. On the origin of cancer cells. Science 1956; 123:309-314.
18. Hoekstra O, Ossenkoppele GJ, Golding R, et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med 1993; 34:1706-1710.
19. Paul R. Comparison of F-18-2-FDG and gallium-67 citrate: imaging for detection of lymphoma. J Nucl Med 1987; 28:288-292.
20. Okada J, Yoshikawa K, Imazeki K, et al. Positron emission tomography using fluorine-18-fluorodeoxy-glucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992; 33:325-329.
21. Lapela M, Leskinen S, Minn H, et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 1995; 9:3522-3527.
22. Leskinen-Kallio S, Ruotsalainen U, Ngren K, Teräs M, Joensuu H. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study. J Nucl Med 1991; 32:1211-1218.
23. Rodriguez M, Rehn S, Ahlström H, Sundström C, Glimelius B. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 1995; 36:1790-1796.
24. Okada J, Yoshikawa K, Imazeki K, et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med 1991; 32:686-691.
25. Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-(F-18)-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994; 190:111-116.
26. Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 1991; 32:1485-1490.
27. Rozental JM, Levine RL, Nickles RJ, Dobkin JA. Glucose uptake in glioma after treatment: a positron emission tomographic study. Arch Neurol 1989; 46:1302-1307.
28. Munker R, Stengel A, Stäbler A, Hiller E, Brehm G. Diagnostic accuracy of ultrasound and computed tomography in the staging of Hodgkin's disease. Cancer 1995; 76:1460-1466.
29. Pond GD, Castellino RA, Horning S, Hoppe R. Non-Hodgkin lymphoma: influence of lymphography, CT, and bone marrow biopsy on staging and management. Radiology 1989; 170:159-164.
30. Rosenberg SA, Berard CW, Brown BW, et al. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical use. Cancer 1982; 49:2112-2135.
31. Schmidlin P. Improved iterative image reconstruction using variable projection binning and abbreviated convolution. Eur J Nucl Med 1994; 21:930-936.
32. Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med 1995; 36: 1836-1839.
33. Dorfman RE, Alpern MB, Gross BH, Sandler MA. Upper abdominal lymph node size determined with CT. Radiology 1991; 180:319-322.
34. Einstein DM, Singer AA, Chilcote WA, Desai RK. Abdominal lymphadenopathy: spectrum of CT findings. RadioGraphics 1991; 11:457-472.
35. Wegener OH. Mediastinum. In: Ganzkörpercomputertomographie. 2nd ed. Berlin, Germany: Blackwell, 1992; 141-143. [German]
36. Gross BH, Glatzer GM, Orringer MB, Spizarny DL, Flint A. Bronchogenic carcinoma metastatic to normal-sized nodes: frequency and significance. Radiology 1988; 166:71-74.
37. Eichhorn T, Schroeder HG, Glanz H, et al. Histologisch kontrollierter vergleich von palpation und sonographie bei der diagnose von halslymphknotenmetastasen. Laryngol Rhinol Otol 1987; 66:266-274. [German]
38. Castellino R, Hoppe R, Blank N, et al. Computed tomography, lymphography, and staging laparotomy: correlations in initial staging of Hodgkin's disease. AJR 1984; 143:37-11.
39. Kaplan HS. Hodgkin's disease. 2nd ed. Cambridge, Mass: Harvard University Press, 1980.
40. Jabour BA, Choi Y, Hoh C, et al. Extracranial head and neck: PET imaging with 2-[F-18]fluoro-2-deoxy-glucose and MR imaging correlation. Radiology 1993; 186: 27-35.
41. Quetz JU, Rohr S, Hoffmann P, et al. B-image sonography in lymph node staging of the head and neck area: a comparison with palpation, computerized and magnetic resonance tomography. HNO 1991; 18:3961-3963.
42. Fishman EK, Kuhlman JE, Jones RJ. CT of lymphoma: spectrum of disease. RadioGraphics 1991; 11:647-669.
43. Castellino R. Diagnostic imaging studies in patients with newly diagnosed Hodgkin's disease. Ann Oncol 1992; 3(suppl 4):45-47.
44. Mansfield C, Fabian C, Jones S, et al. Comparison of lymphangiography and CT scanning in evaluating abdominal disease in stages III and IV Hodgkin's disease. Cancer 1990; 66:2295-2299.
45. Hoane BR, Shields AF, Porter BA, Borrow JW. Comparison of initial lymphoma staging using computed tomography and magnetic resonance. Am J Hematol 1994; 47:100-105.
46. Larcos G, Farlow DC, Antico VF, Gruenewald SM, Boyages J. The role of high dose 67-gallium scintigraphy in staging untreated patients with lymphoma. Aust NZ J Med 1994; 24:5-8.
47. Merral NW, Plevin R, Gould GW. Growth factors, mitogens, oncogens and the regulation of glucose transport. Cell Signal 1993; 6:667-675.
48. Birnbaum MJ, Haspel HC, Rosen OM. Transformation of rat fibroblasts by FSV rapidly increases glucose transporter gene transcription. Science 1987; 235:1495-1496.
49. Scott WJ, Gobar LS, Hauser LG, et al. Detection of scalene lymph node metastases from lung cancer: positron emission tomography. Chest 1995; 107:1174-1176.
50. Braams JVV, Pruim J, Freling NJM, et al. Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med 1995; 36:211-216.
51. Glatting G, Rentschler M, Reske SN. Theoretical model for the assessment of detectability of small lesions depending on lesion size and lesion contrast for 2D-and 3D-PET (abstr). Eur J Nucl Med 1996; 23:1239.
52. Kubota R, Yamada S, Ishiwata K, Tamahashi N, Ido T. Intramural distribution of FDG in vivo: high accumulation in macrophages and granulation tissue studied by microautoradiography. J Nucl Med 1992; 33:1972-1980.
53. Wahl R, Quint LE, Greenough RL, Meyer CR, White RI, Orringer MB. Staging of mediastinal non-small cell lung cancer with FDG-PET, CT and fusion images: preliminary prospective evaluation. Radiology 1994; 191:371-377.
54. Patz EF, Lowe VJ, Hoffman JM, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993; 188:487-190.
55. Dewan NA, Gupta NC, Redepenning LS, Phalen JJ, Frick MP. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules: potential role in evaluation and management. Chest 1993; 104:997-1002.
56. 18F]fluorodeoxyglucose. Ann Thorac Surg 1994; 58:698-703.
57. Lowe VJ, Hoffman JM, DeLong DM, Patz EF, Coleman RE. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 1994; 35:1771-1776.
58. Dewan NA, Reeb SD, Gupta NC, Gobar LS, Scott WJ. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions: a comparative risk-benefit analysis. Chest 1995; 108:441-146.
59. Hoffman JM, Waskin HA, Hanson MW, Gray L, Rosenfeld S, Coleman E. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med 1993; 34:567-575.
60. Shirkoda A, Ros R, Farah J, Staab EV. Lymphoma of the solid abdominal viscera. Radiol Clin North Am 1990; 28:785-799.